HEAL Initiative: Rapidly Assessing the Public Health Impact of Emerging Opioid Threats (UG1 - Clinical Trial Not Allowed) | RFA DA 23 045

Opportunity Information: Apply for RFA DA 23 045

The HEAL Initiative funding opportunity titled "Rapidly Assessing the Public Health Impact of Emerging Opioid Threats" (RFA-DA-23-045) is a National Institutes of Health (NIH) cooperative agreement (UG1) focused on helping public health and clinical systems keep pace with fast-changing, increasingly potent illicit opioid markets. The core problem the program is trying to solve is that new synthetic opioids and opioid-like drugs are appearing quickly, often derived from published scientific and patent literature, and the field lacks standardized, validated, widely deployable ways to detect and characterize them. As a result, frontline clinicians, harm reduction programs, toxicology labs, and public health agencies can struggle to identify what people have actually taken, how dangerous it is, and what kind of response is most appropriate.

A major driver behind this opportunity is the reality that fentanyl and fentanyl-related analogs have reshaped the overdose landscape, contributing to sharp increases in mortality and complicating stabilization and harm reduction. The opportunity highlights that even when fentanyl test strips detect fentanyl analogs, they typically collapse results into a single "fentanyl" category. That grouping can mask meaningful differences among analogs in potency, duration of action, and response to antagonists such as naloxone. The description points to the way early reports about fentanyl being unusually long-lasting and difficult to reverse became less prominent as the drug supply changed (for example, when carfentanil, an ultra-potent and long-lasting analog, became less common). This illustrates the larger point: the clinical picture and the public health risk can shift as specific compounds cycle in and out of circulation, so detection and interpretation need to be more precise and adaptable than they are today.

The immediate emerging threat emphasized in the announcement is the rise of nitazenes (often described as ultra-potent opioids), which may be overlooked in many jurisdictions because validated analytical standards and protocols are not yet widely available. Unlike fentanyl, where some point-of-care tools exist, nitazene urine test strips are not yet available, leaving clinicians and public health responders without an easy way to recognize nitazene exposure in real time. The FOA is therefore geared toward accelerating the development and distribution of tools that can detect nitazenes across the range of settings where detection matters, including clinical environments, public health surveillance, and potentially harm reduction contexts. A related theme is that people who use drugs generally cannot know whether what they purchased contains nitazenes or specific fentanyl analogs, which increases overdose risk and makes targeted warnings and interventions harder.

Beyond nitazenes, the funding opportunity is designed with an eye toward the next waves of drug innovation. It explicitly notes that more novel substances are likely to keep emerging for years, and it builds in support for awardees to rapidly apply their methods and expertise to future threats as they appear. In practice, that means projects are expected not just to create a one-off assay or tool for a single compound, but to strengthen the broader capacity to rapidly detect, validate, and deploy identification approaches as the illicit market evolves.

Administratively, this is a discretionary NIH opportunity under the HEAL Initiative, using a cooperative agreement mechanism (UG1), which generally means NIH will have substantial programmatic involvement during the project period compared with a standard grant. The listing indicates "Clinical Trial Not Allowed," signaling that applicants should propose research and development activities that do not meet NIH's definition of a clinical trial (for example, tool development, analytical validation, surveillance methods work, or implementation-oriented activities that are not testing health-related interventions on human subjects with prospective assignment). The Funding Activity Category is listed as Education and Health, and the CFDA numbers associated with the opportunity are 93.213, 93.273, and 93.279.

Eligibility is broad and includes many types of domestic and non-domestic organizations. Eligible applicants include state, county, and local governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized tribal governments; other tribal organizations; public housing authorities/Indian housing authorities; nonprofits with and without 501(c)(3) status; for-profit organizations (other than small businesses); and small businesses. The announcement also explicitly calls out additional eligible groups such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), faith-based and community-based organizations, eligible federal agencies, regional organizations, U.S. territories or possessions, and foreign organizations.

Key identifying details from the source data are: Funding Opportunity Title "HEAL Initiative: Rapidly Assessing the Public Health Impact of Emerging Opioid Threats (UG1 - Clinical Trial Not Allowed)," Funding Opportunity Number RFA-DA-23-045, agency NIH, and an original closing date of 2023-02-02, with a creation date of 2022-07-07. The award ceiling and expected number of awards are not specified in the provided listing.

• The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "HEAL Initiative: Rapidly Assessing the Public Health Impact of Emerging Opioid Threats (UG1 - Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.213, 93.273, 93.279.
• This funding opportunity was created on 2022-07-07.
• Applicants must submit their applications by 2023-02-02. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA DA 23 045

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: